enGene Therapeutics (ENGN) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citizens | Maintained | Market Perform | — | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 | Sep 8, 2026 |
| Morgan Stanley | Downgraded | Equal-Weight → Underweight | — | Jun 18, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $4.00 from $6.00 | Jun 16, 2026 |
| UBS | Maintained | Neutral | $2.00 from $9.00 | May 14, 2026 |
| Piper Sandler | Downgraded | Overweight → Neutral | $4.00 from $7.00 | May 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 from $25.00 | May 8, 2026 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $2.00 from $25.00 | May 8, 2026 |
| Guggenheim | Downgraded | Buy → Neutral | — | May 8, 2026 |
| Citizens | Downgraded | Market Outperform → Market Perform | — | May 8, 2026 |
| WBB Securities | Initiated Coverage | Buy | $21.50 | Apr 13, 2026 |
| Oppenheimer | Maintained | Outperform | $30.00 from $33.00 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Mar 9, 2026 |
| UBS | Maintained | Neutral | $10.00 from $4.00 | Nov 12, 2025 |
| Oppenheimer | Maintained | Outperform | $33.00 from $30.00 | Nov 12, 2025 |
| Morgan Stanley | Maintained | Overweight | $19.00 from $18.00 | Nov 12, 2025 |
| Citizens | Maintained | Market Outperform | $21.00 from $18.00 | Nov 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Sep 12, 2025 |
| Morgan Stanley | Maintained | Overweight | $18.00 from $19.00 | Sep 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $25.00 | Sep 8, 2025 |
Frequently asked questions
Is ENGN a buy, sell, or hold?
Analysts covering enGene Therapeutics currently average a Hold rating: 4 buy, 5 hold and 1 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ENGN?
On Sep 9, 2026, Citizens maintained enGene Therapeutics at Market Perform.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.